126 related articles for article (PubMed ID: 15103706)
1. Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation.
Bergen HR; Abraham RS; Johnson KL; Bradwell AR; Naylor S
Biomed Chromatogr; 2004 Apr; 18(3):191-201. PubMed ID: 15103706
[TBL] [Abstract][Full Text] [Related]
2. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
3. Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kappa1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry.
Lim A; Wally J; Walsh MT; Skinner M; Costello CE
Anal Biochem; 2001 Aug; 295(1):45-56. PubMed ID: 11476544
[TBL] [Abstract][Full Text] [Related]
4. Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.
Olsen KE; Sletten K; Westermark P
Biochem Biophys Res Commun; 1998 Oct; 251(2):642-7. PubMed ID: 9792827
[TBL] [Abstract][Full Text] [Related]
5. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
[TBL] [Abstract][Full Text] [Related]
6. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
7. A case of primary immunoglobulin light chain amyloidosis with a delayed appearance of Bence Jones protein in urine.
Kurusu A; Yamada T; Yamaji K; Nishitani M; Tashiro K; Maeda K; Horikoshi S; Shirato I; Rinno H; Tomino Y
Nephrology (Carlton); 2004 Jun; 9(3):122-5. PubMed ID: 15189172
[TBL] [Abstract][Full Text] [Related]
8. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
[TBL] [Abstract][Full Text] [Related]
9. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion.
Alyanakian MA; Abbas A; Delarue R; Arnulf B; Aucouturier P
Am J Hematol; 2004 Apr; 75(4):246-8. PubMed ID: 15054820
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
[TBL] [Abstract][Full Text] [Related]
11. Interaction between glycosaminoglycans and immunoglobulin light chains.
Jiang X; Myatt E; Lykos P; Stevens FJ
Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
Shaheen SP; Levinson SS
Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
[TBL] [Abstract][Full Text] [Related]
14. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum.
Lavatelli F; Brambilla F; Valentini V; Rognoni P; Casarini S; Di Silvestre D; Perfetti V; Palladini G; Sarais G; Mauri P; Merlini G
Biochim Biophys Acta; 2011 Mar; 1814(3):409-19. PubMed ID: 21215335
[TBL] [Abstract][Full Text] [Related]
15. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.
Tate JR; Mollee P; Dimeski G; Carter AC; Gill D
Clin Chim Acta; 2007 Feb; 376(1-2):30-6. PubMed ID: 16945362
[TBL] [Abstract][Full Text] [Related]
16. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
17. Current concepts of the formation and composition of amyloid.
Glenner GG
Ann Clin Lab Sci; 1975; 5(4):257-63. PubMed ID: 808999
[TBL] [Abstract][Full Text] [Related]
18. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
20. Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains.
del Pozo Yauner L; Ortiz E; Sánchez R; Sánchez-López R; Güereca L; Murphy CL; Allen A; Wall JS; Fernández-Velasco DA; Solomon A; Becerril B
Proteins; 2008 Aug; 72(2):684-92. PubMed ID: 18260098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
